a lonely feeling
is all around this webpage
can't find one like it
If you are certain you have the correct web address but are encountering an error, please contact the Site Administration. Thank you.
You are seeing this haiku because the page you were looking for cannot be found.
We apologize for the inconvenience, but the page you were trying to access is not at this address. You can use the links below to help you find what you are looking for.
You might have been looking for…
-
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials
© 2020, Springer Science+Business Media, LLC, part of Springer Nature. Background: Resistance to gemcitabine chemotherapy is common in patients with pancreatic ...
-
A Phase IB open-label, dose-escalation study of NUC‑1031 in combination with carboplatin for recurrent ovarian cancer.
PURPOSE: NUC-1031 is a first-in-class ProTide modification of gemcitabine. In PRO-002, NUC‑1031 was combined with carboplatin in recurrent ovarian cancer (OC). ...
-
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
BACKGROUND: Gemcitabine is used to treat a wide range of tumours, but its efficacy is limited by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate ...
- NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival
- Is the α/β for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031 (multiple letters) [4]